6 INCOME TAX (CONTINUED) Total estimated tax losses not brought to account at 30 June 2026 for the consolidated tax group, comprising INOVIQ Limited and its wholly owned subsidiary Sienna Cancer Diagnostics Ltd (Sienna), totals $9,750,355 (2025: $8,522,318). This total includes losses incurred by Sienna since 1 July 2015 being the period from which point onwards an external tax specialist determined tax losses would be accessible to the Group after application of the Income Tax Assessment Act 1997 loss transfer provisions, encompassing the requirement to satisfy either the Continuity of Ownership Test (COT) or Similar Business Test (SBT). Tax losses incurred by foreign subsidiary INOVIQ Inc. (formerly Sienna Cancer Diagnostics Inc.) are not included in estimated tax losses not brought to account. It is not probable that the Group will be in a position to utilise these tax losses in future. Deferred tax assets have not been brought to account at 30 June 2026 because the directors do not believe it is appropriate to regard realisation of the future tax benefit as probable. These benefits will only be obtained if: (i) the Group derives future assessable income of a nature and of an amount sufficient to enable the benefit from the deduction for the loss to be realised; (ii) the Group complies with the conditions for the deductibility imposed by law including the continuity of ownership and/or business tests; and (iii) no changes in tax legislation adversely affect the Group in realising the benefit from the deduction for the loss. 7 CASH AND CASH EQUIVALENTS & CASH FLOW INFORMATION As at 30 June 2026 $ As at 30 June 2025 $ Cash at bank 1,103,441 520,923 Term deposits* 8,250,000 6,000,000 Cash and cash equivalents comprise cash at bank 9,353,441 6,520,923 * All have a term of three months or less from the date of commencement of the deposit, are not held for investment purposes and are readily convertible into cash at the end of their terms and will be used to fund short term operational cash requirements. Net loss after income tax (7,505,123) (6,932,280) Share based payments expense (87,072) 824,563 Depreciation and amortisation 1,330,261 1,380,112 Unrealised foreign exchange (gain)/loss 209,121 (96,658) Changes in Assets & Liabilities: (Increase)/decrease in receivables (393,868) (398,499) (Increase)/decrease in inventories 9,057 (28,962) Increase/(decrease) in payables (5,680) 413,281 Increase/(decrease) in provisions 23,142 91,262 (Increase)/decrease in prepayments 40,099 84,507 Net cash used in operating activities (6,380,063) (4,662,673) Notes to the Financial Statements continued for the year ended 30 June 2026 46 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3